Betting on Benlysta, GSK nails down $3.6 billion HGS deal
GlaxoSmithKline is buying Human Genome Sciences for $3.6 billion, giving it full ownership of Benlysta, along with albiglutide and darapladib, after months of M&A intrigue.
View ArticleMerck filings could expand heart division
The company said Monday that it's on track to file applications with US and European regulators for two cardiovascular-disease therapies.
View ArticleCompany news: Pfizer, fish oil
A study says fish oil doesn't lower the risk of heart disease, and the World Health Organization greenlights Pfizer's Prevnar 13 for adults 50 and up.
View ArticleCompany news: Janssen, Pfizer, BMS and Boehringer Ingelheim
Janssen's prostate cancer pill Zytgia got an OK for use in an earlier line of therapy, and drugmakers Pfizer, Bristol-Myers Squibb and Boehringer Ingelheim released new data on blood thinners Eliquis...
View ArticleMerck Tredaptive stalls in US
Disappointing Phase III results are scrambling the drugmaker's plans for the CETP drug.
View ArticleTrial designed with crowd input gets FDA signoff
Transparency Life Sciences is tapping the wisdom of the crowd, with FDA's imprimatur, in an effort to make the drug development process more sustainable.
View ArticleYear-end approval clears Eliquis for US launch
Eliquis was approved Friday for preventing strokes in patients with nonvalvular atrial fibrillation, becoming the third oral anticoagulant to reach the US market.
View ArticleCompany news: Biogen Idec, Merck
Biogen pulls ALS treatment from its pipeline, Merck resubmits cholesterol combo to FDA
View ArticleCDC talks stroke, heart-attack prevention in Spanish
The Million Hearts initiative just got a Spanish-language rollout, and the culturally sensitive content is starting to gain attention.
View ArticleBusiness briefs: United Concordia, FDA
United Concordia finds a way to slash healthcare costs for $4,000 a year, and FDA goes on tour to promote tighter compounding oversight
View ArticleSuccess in emerging markets hinges on broad network
Execs told Booz & Co researchers that the relationships web in emerging markets needs to be deeper than one-on-one sales pitches.
View ArticleStudies show cost doesn't drive everything
Two studies show that it's not enough to focus on cost to alter healthcare.
View ArticleMayo device helps monitor heart patients from afar
Device maker Preventice says the peel-and-stick monitor has the potential to go beyond the critical care market and into the sports world.
View ArticleBusiness briefs: AbbVie, AstraZeneca, Valeant, Merck, Novo Nordisk
AbbVie's Niaspan pricing gets a hard look; AstraZeneca buys up heart drug and company; Valeant expands eye care portfolio with B&L; Merck halts Parkinson's study; Novo explores liraglutide weight...
View ArticleAmarin launches unbranded triglyceride info site
The launch is part of its overall marketing program, which includes deploying 275 sales reps to market the drug which officially launched in January.
View ArticleAstraZeneca buys respiratory specialist Pearl Therapeutics
The drug maker eases the burden on its Symbicort franchise by scooping up Pearl for $510 million.
View ArticleWeight-loss category expands by one
Eisai brings Belivq to 20,000 US pharmacies, along with 200 sales reps and a physician marketing push.
View ArticleBusiness briefs: Boehringer Ingelheim, Teva, Medicare
Good and bad news about Pradaxa; Plan B decision not deemed a big threat to Teva's sales; Study says Medicare patients more likely to receive brand-name medications than VA patients
View ArticleBusiness briefs: Medtronic, AMA, Komen, GSK, Lilly, AZN
Studies undercut Medtronic spine treatment benefit, AMA wars over obesity classification, Komen gets a new CEO, GSK offloads thrombosis meds, Lilly gains diabetes treatment, AZN chooses new site
View ArticleBusiness briefs: Astellas, ADA, AJMC, AARP
Astellas teams up with Cytokinetics for muscle weakness research; ADA says lifestyle changes don't protect diabetics' hearts; AJMC talks pharmacists as diabetes counselors; and AARP helps with...
View Article
